PANASONIC/KOSE
6.12.2019 03:39:11 CET | Business Wire | Press release
Panasonic Corporation is collaborating with KOSÉ Corporation to conduct a joint verification test using Snow Beauty Mirror, a system under development by Panasonic, with the aim of offering personalized proposals at Maison KOSÉ, a store which is due to open on December 17. Through this initiative, Panasonic will help make new personalized proposals that meet the diverse needs of its customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005971/en/
People’s values and lifestyles are becoming increasingly diverse. In today’s world, everyone requires something different from their cosmetics. Meanwhile, customers are confronted with a deluge of information through the Internet and social media, which sometimes makes it difficult for them to select cosmetics that really suit their needs. A solution to this conundrum is personalized proposals which utilize digital technologies and data to introduce individuals to the optimal products and services.
Maison KOSÉ is a new type of concept store, a place where people will be able to come and experience these personalized proposals firsthand using Snow Beauty Mirror. Visitors will also be able to try out Customized Sheets (provisional name), which adopts the Make-up Sheet technology currently under development at Panasonic.
Functions of Snow Beauty Mirror and content of verification test
1. Skin analysis
All customers need to do is sit in front of the mirror. The system then analyzes the customer’s skin profile and displays numerical data instantly on the mirror. Contactless sensors embedded in the mirror detect the condition of both the skin’s surface and below the surface. With a degree of precision on par with medical devices, the system detects not only spots, wrinkles, smile lines, pores and skin tone, but also hidden spots otherwise invisible to the naked eye. Then, based on digital counselling and analysis results, the system recommends the optimal package for each individual customer from among KOSÉ’s products and services spanning multiple brands*1 . This function utilizes facial recognition and image processing technologies used in digital cameras, et al.
2. Ideal face image system
Combining genetic algorithms, developed as a joint venture between KOSÉ and Meiji University, with Panasonic’s image processing technologies has enabled the creation of a system which makes it possible to visualize a person’s “ideal face” from facial image data—that is, how the customer would really like to appear. Snow Beauty Mirror’s high-precision skin analysis function detects the customer’s skin conditions in terms of pores, spots and wrinkles, as well as the skin’s tones and brightness, and adjusts the parameters of this data to create around 500,000 facial image patterns. The customer selects their preferred facial image from among randomly displayed facial images, generating their ideal face in a short time. The system can visualize the differences between the customer’s ideal face and current appearance, while providing tips on the perfect foundation tone, texture and application techniques to help them get closer to their ideal face.
3. Customized Sheets which apply Make-up Sheet technology
Currently under development at Panasonic, Make-up Sheets are ultra-thin*2 cosmetic sheets printed with tones that perfectly match the customer’s skin. They combine skin analysis data from Snow Beauty Mirror, and the company’s proprietary printing technology. Customers simply need to stick the sheets over areas of concern on their cheeks or temples.
In this verification test, Panasonic will combine its Make-up Sheet technology, proprietary skin tone analysis technology, and printing technology with KOSÉ’s extensive knowledge of cosmetic development. The aim is to create Customized Sheets (provisional name) that achieve a natural color match and an ideal fit with the customer’s skin.
Panasonic will continue to fuse its cutting-edge technologies with KOSÉ’s development capabilities in cosmetics to expand the scope of Snow Beauty Mirror, pursuing possibilities that go beyond the field of beauty treatment. In this way, the company will meet the diverse needs of its customers and better contribute to society through improved QOL.
Notes:
*1. KOSÉ Group’s skin care brands, excluding ALBION
*2. Thickness of 100 nanometers (one nanometer = one billionth of a meter)
About Maison KOSÉ
A fun concept store stocking and linking all KOSÉ brands*3 , providing customers with an early chance to try a range of new software and hardware relating to cosmetics and beauty treatment. The store facilitates new forms of communication which fuse digital and experiential approaches, exploring new possibilities for the next generation of cosmetic experiences and working to connect customers digitally to the store. It also serves as a place of communication with customers, functioning as a seat of learning where information and experiences can be quickly fed back into the company.
*3 Excluding some products
About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 87 associated companies worldwide, recording consolidated net sales of 8.003 trillion yen for the year ended March 31, 2019. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global .
Source: https://news.panasonic.com/global/press/data/2019/12/en191206-2/en191206-2.html
Related Links
[Video] Make-up Sheet / Technology & Innovation of Panasonic
https://channel.panasonic.com/contents/25818/
[Video] Solving skin concerns with innovation using the “Make-up Sheet” [Panasonic]
https://channel.panasonic.com/contents/25819/
Brand Story | Panasonic
https://www.panasonic.com/global/corporate/brand/story.html
Panasonic R&D Overview | Panasonic
https://www.panasonic.com/global/corporate/technology-design/r-and-d.html
Breakthrough Technology | Panasonic
https://www.panasonic.com/global/corporate/technology-design/technology.html
KOSÉ Corporation
https://www.kose.co.jp/global/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20191205005971/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
